Samsung Bioepis ‘Setting A High Bar’ For Next Wave Of Biosimilars
Korea-Based Company Will Also Target ‘Value-Added Features’
In the wake of parent company Samsung Biologics completing its full acquisition of Samsung Bioepis, the Korea-based biosimilars player has told Generics Bulletin that it will be a “more robust company,” as it applies more rigorous standards to replenishing its pipeline of biosimilar candidates.
You may also be interested in...
Samsung Bioepis has confirmed launch plans for its citrate-free, high-concentration Hadlima (adalimumab) biosimilar after it was waved through the Canadian healthcare regulator.
Biogen’s stake in Samsung Bioepis has been fully acquired by former partner Samsung Biologics, following an announcement of the deal in January.
Amgen has reported positive preliminary results from a Phase III study for its ABP 654 proposed ustekinumab biosimilar rival to Stelara, for which the firm also intends to pursue an interchangeability designation.